Breast Cancer Drug Discoveries: what the future holds 2008

Publication Date	December 2008
Publisher	Espicom
Product Type	Report
Pages	200
ISBN Number	not applicable
Product Code	ESP00385

Buy this product or for assistance call +44 20 7060 7474

PDF £795.00$1322 | €890

FAX Order above formats by FAX

Summary

This report provides a comprehensive examination of all major breast cancer treatments, critical competitive evaluation of current and up and coming products and sales forecasts to 2014.

Content

Executive Summary
- The Facts
  - What Is Bc And How Does It Affect Patients?
  - Risk Factors
  - Diagnosis
  - Stages Of The Disease
- Patient Statistics
  - The Us
  - Europe
  - Japan
Patient Model
- The Prevalence Of People Living With Bc Will Increase By 26.6 Per Cent By 2014
Drug Growth Drivers
Drug Growth Risks/Dampeners
The Breast Cancer Market
- Bc Therapy Sales Split
- Global Bc Sales Split
  - Us Market
  - European Market
  - Japanese Market
- The Players
- Players And Products In 2007
- Players And Products In 2014
Current Treatments
- Surgery
- Radiation
- Hormonal Therapy
  - Leading Brands
  - Current Products' Patent Exposure
- Chemotherapy
  - Leading Brands
  - Current Products' Patent Exposure
- Molecular Targeted Therapy
  - Leading Brands
  - Curent Products' Patent Exposure
Analysis Of Leading Brands
- Hormonal Therapy
  - Anti-Oestrogen Drugs
  - Evista
  - Faslodex
  - Nolvadex
  - Aromatase Inhibitors
  - Arimidex
  - Aromasin
  - Femara
  - Lhrh Agonists
  - Zoladex
- Chemotherapy
  - Taxanes
  - Abraxane
  - Taxol
  - Taxotere
  - Antimetabolites
  - Gemzar
  - Xeloda
  - Epothilone Analogues
  - Ixempra
- Molecular Targeted Therapy
  - Avastin
  - Herceptin
  - Tykerb
Sales Forecast Of Current Bc Drugs
Research & Development Of Bc Drugs
Analysis Of Phase Iii Drugs
- Molecular Targeted Therapy
  - Angiogenesis Inhibitors
  - Armala
  - Imc-1121
  - B
  - Sutent
  - Her2/Neu Dimerisation Inhibitor
  - Pertuzumab
- Hormonal Therapy
  - Arzoxifene
Global Sales Forecasts Of Phase Iii Bc Drugs 2007a - 2014e
- Model Assumptions
Analysis Of Phase Ii Drugs
- Molecular Targeted Therapy
  - Parp Inhibitors
  - Azd2281
  - Bsi-201
  - Therapeutic Vaccines
  - Ae37
  - Mva-Bn-Her2
  - Neuvax
  - Angiogenesis Inhibitor
  - Axitinib
  - Igf-1r Inhibitors
  - Ave1642
  - Imc-A12
  - Heat Shock Protein Inhibitors
  - Tanespimycin
  - Anti-Phospholipid Therapy
  - Bavituximab
- Chemotherapy
  - Sagopilone
- Hormonal Therapy
  - Zk-Pra
Competitor Ratio Analysis
- Competitor Ratio Analysis Criteria
Competitor Ratio Analysis - Products
Competitor Ratio Analysis - Companies
- Winners & Losers
- Winners
- Losers
Discontinuation Of Drugs
Appendix 1: Diagnostic Assays
- Her2 Diagnostics
- virtual Cancer Patient Technology - Optimata
- Brca Tests
- Bc Detection
- Future Advances In Diagnostics
Appendix 2: Patient Model
Appendix 3: Global Bc Drug Sales
Appendix 4: Phase Transition Probability
Glossary
Bibliography
Website References
Acronyms
Index Of Tables
- Tmn Classification In Bc
- Us Bc Statistics
- European (Top 5 Countries) Bc Statistics
- Japanese Bc Statistics
- Summary Of Patient Population Forecasts In The Top 7 Countries (2007-2014e)
- Current Major Hormonal Therapies
- Comparison Of Leading Hormonal Therapies
- Patent Exposure Of Leading Brands
- Chemotherapy Combinations Currently Prescribed In Early-Stage Bc
- Patent Exposure Of Leading Brands
- Proposed Filings Of New Indications For Avastin
- Global Sales Of Leading Bc Drugs 2007 A-2014 E (Us$ Millions)
- Products In Clinical Development For The Treatment Of Bc
- New Drugs In Phase Iii Development To Treat Bc
- Sales Forecasts Of Phase Iii Developmental Bc Drugs (Us$ Million)
- New Drugs In Phase Ii Development To Treat Bc
- Key Bc Drugs On The Market By 2014
- Company Competitor Ratio Analysis Scores
- Summary Of Key Companies And Drugs In The Bc Market By 2014
- Bc Drugs Discontinued During Development
- Summary Of Us Bc Patient Population Forecasts
- Summary Of European (Top 5) Bc Patient Population Forecasts
- Summary Of Japanese Bc Patient Population Forecasts
- Global Bc Drugs Sales 2007 A-2014
- Probability Of Launch
Index Of Charts
- Schematic Of The Breast
- Bc Market Opportunities
- Impact Of Biomarker Identification On Bc Patients
- Impact Of Biomarker Identification On Dose Selection Studies In Bc Patients
- Global Bc Market By Therapy Class (2007 A)
- Global Bc Market By Therapy Class (2014 E)
- Global Sales Split By Region (2007)
- Bc Us Drugs Sales Split (2007)
- Market Share Of Bc Players By Sales (2007a)
- Global Market Share Of Bc Players By Sales (Dec 2014e)
- Schematic Of Treatment Options In Bc
- Hormones Affecting Bc
- Mode Of Action Of Anti-Oestrogens
- Evista - Invasive Bc Incidence - Star Trial
- Evista - Invasive Bc Placebo Trials
- Evista Bc Sales (2007e-2014e)
- Efect Trial Design - Fasoldex Vs Aromasin
- Faslodex Sales (2005a-2014e)
- Nolvadex Sales (2005a-2014e)
- Mode Of Action Of Aromatase Inhibitors
- Clinical Trial Data Drives Growth Of Bc Products
- Arimidex Sales (2005a-2014e)
- Pfizer's Broad Oncology Pipeline
- Aromasin Sales (2005a-2014e)
- Market Potential For Femara In Extended Adjuvant Setting
- Femara Sales (2005a-2014e)
- Zoladex Sales (2005a-2014e)
- Clinical Efficacy Of Abraxane In Bc
- Abraxane Bc Sales (2005a-2014e)
- Taxol Bc Sales (2005a-2014e)
- Taxotere Growth
- Taxotere Bc Sales (2005a-2014e)
- A) Time-To-Disease Progression And B) Overall Response Rate Of Metastatic Bc To Gemzar Treatment
- Gemzar Bc Sales (2005a-2014e)
- Xeloda Bc Sales (2005a-2014e)
- Ixabepilone: Preclinical Synergy With Targeted Therapies
- Ixempra Bc Sales (2007a-2014e)
- Avastin Clinical Trials
- Avastin Bc Sales (2007a-2014e)
- Mechanism Of Action Of Herceptin
- A) Herceptin Positive And Negative Bc Patient Split And B) Marketing Opportunities For Herceptin In Chemotherapy Patients
- Herceptin Bc Sales (2005a-2014e)
- Gsk To Target A Broad Bc Population With Tykerb
- Bc Treatment Opportunities
- Tykerb Sales (2007a-2014e)
- Armala Bc Sales (2012e-2014e)
- Imc-1121
- B Bc Sales (2013e-2014e)
- First-Line Phase Iii Bc Trial
- Second/Third-Line Phase Iii Bc Trial
- Pfizer's Bc Clinical Development Programme
- Sutent Bc Sales (2012e-2014e)
- Pertuzumab Bc Sales (2012e-2014e)
- Arzoxifene Bc Sales (2010e-2014e)
- The Role Of Hsp90 In Chaperoning Client Proteins
- Company Competitor Ratio Analysis Scores